CARGO-CRG-022-101-LBCL
Phase II
OPEN TO ACCRUAL
An Open-Label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-Cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma (Firce-1)